Clinical Trial Update: A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). [Phase 2]

View source ↗

Summary

Phase 2 study of MBG453 in combination with hypomethylating agents for intermediate/high/very high risk myelodysplastic syndrome; the trial was terminated and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• MBG453

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED | Results posted: 2023-07-07